Growth pattern and clinical outcome of COVID-19 cases
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/12/038812
- Lead Sponsor
- Bhabha Atomic Research Centre hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All the laboratory confirmed cases from April 2020 to April 2021 will be included for the analysis.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the growth pattern of the confirmed COVID-19 Cases in community availing comprehensive healthcare facility at Mumbai, India during April 2020 to April 2021.Timepoint: NA as it is a retrospective Data analysis
- Secondary Outcome Measures
Name Time Method 1)To study the growth of the COVID-19 cases across the township residents and non-township patients under healthcare scheme. <br/ ><br>2)To estimate the doubling rate, R0 (Reproduction rate) <br/ ><br>3)To study the comorbidity status and outcome evaluation of patients.Timepoint: NA as it is a retrospective Data analysis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link SARS-CoV-2 viral load to clinical outcomes in CTRI/2021/12/038812 urban observational study?
How do comorbidities like diabetes or hypertension influence disease progression in CTRI/2021/12/038812 compared to standard-of-care management?
Which biomarkers (e.g., IL-6, C-reactive protein) correlate with severe outcomes in CTRI/2021/12/038812's urban COVID-19 cohort?
What adverse events (e.g., ARDS, cytokine storm) are reported in CTRI/2021/12/038812 and how are they managed in resource-limited urban settings?
How does CTRI/2021/12/038812's observational data compare to trials of antivirals like remdesivir or monoclonal antibodies in B972- disease subtypes?